A cluster randomised trial evaluating the clinical effectiveness and cost of telemedicine delivered multidisciplinary meetings in breast cancer

ISRCTN	ISRCTN67592929
DOI	https://doi.org/10.1186/ISRCTN67592929
Protocol serial number	1217319
Sponsor	UK Department of Health Research and Development
Funders	Department of Health (UK) - Research and Development, Big Lottery Fund (UK)

Submission date: 13/09/2005
Registration date: 11/11/2005
Last edited: 09/05/2012

Recruitment status: No longer recruiting
Overall study status: Completed
Condition category: Cancer

Prospectively registered

Protocol

Statistical analysis plan

Results

Individual participant data

Plain English summary of protocol

Not provided at time of registration

Contact information

Dr Ian Kunkler
Scientific

Oncology Department
Western General Hospital
Crewe Road South
Edinburgh
EH4 2XU
United Kingdom

Phone	+44 (0)131 537 2213
Email	iankunkler@yahoo.com

Study information

Primary study design	Interventional
Study design	Randomised controlled trial
Secondary study design	Randomised controlled trial
Study type	Participant information sheet
Scientific title
Study acronym	TELEMAM
Study objectives	Decision making in breast cancer management at a multidisciplinary team (MDT) meeting is as clinically effective as face-to-face meetings and achieved at lower cost.
Ethics approval(s)	Not provided at time of registration
Health condition(s) or problem(s) studied	Breast cancer
Intervention	Randomised standard face-to-face 'on site' multidisciplinary meetings for breast cancer management (MDTs) at Dumfries and Dunfermline (Arm 1) versus MDTs on Dumfries and Dunfermline patients linked by telemedicine between Dumfries and Edinburgh, and Dunfermline and Edinburgh (Arm 2).
Intervention type	Other
Primary outcome measure(s)	1. Satisfaction with communication process of multidisciplinary decision making for each patient (Interpersonal Communication Satisfaction Scale) 2. Costs of face-to-face and telemedicine delivered decision making 3. Compliance with Scottish Intercollegiate Guidelines Network (SIGN) guidelines of best practice for breast cancer
Key secondary outcome measure(s)	1. Pre- and post-trial attitudes to face-to-face and telemedicine delivered multidisciplinary clinics (Personal Report of Communication Apprehension) 2. Measures of objective patterns of interaction 3. Subjective measures of interaction (Group Behaviour Questionnaire, Group Behaviour Inventory, Group Dimensions Description Questionnaire) 4. Communication content (Interaction Process Analysis) 5. General dimensions of output (satisfaction with communication, group atmosphere, involvement, trust and agreement)
Completion date	31/07/2005

Eligibility

Participant type(s)	Patient
Age group	Adult
Sex	Female
Target sample size at registration	230
Key inclusion criteria	1. Histologically proven breast cancer 2. Requiring decision on treatment of primary or recurrent breast cancer
Key exclusion criteria	Does not match inclusion criteria
Date of first enrolment	24/04/2003
Date of final enrolment	31/07/2005

Locations

Countries of recruitment

United Kingdom
Scotland

Study participating centre

Oncology Department

Edinburgh
EH4 2XU
United Kingdom

Results and Publications

Individual participant data (IPD) Intention to share	No
IPD sharing plan summary	Not provided at time of registration
IPD sharing plan

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results	01/11/2007		Yes	No
Protocol article	protocol	01/10/2005		Yes	No
Participant information sheet	Participant information sheet	11/11/2025	11/11/2025	No	Yes